New England Journal of Medicine DECEMBER 14, 1995

Tissue Plasminogen Activator for Acute Ischemic Stroke

The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group

Bottom Line

The NINDS trial demonstrated that intravenous recombinant tissue plasminogen activator (rt-PA) administered within 3 hours of symptom onset significantly improves functional outcomes at 3 months in patients with acute ischemic stroke, despite an increased risk of symptomatic intracerebral hemorrhage.

Key Findings

1. Patients treated with rt-PA were at least 30% more likely to have minimal or no disability at 3 months compared to those in the placebo group.

2. Symptomatic intracerebral hemorrhage within 36 hours occurred in 6.4% of the rt-PA group compared to 0.6% in the placebo group (p < 0.001).

3. There was no statistically significant difference in 3-month mortality rates between the rt-PA group (17%) and the placebo group (21%) (p = 0.30).

4. Clinical benefits in functional outcomes (measured via Barthel Index, modified Rankin Scale, Glasgow Outcome Scale, and NIHSS) were observed at 90 days despite the lack of significant improvement at 24 hours.

Study Design

Design

RCT

Double-Blind

Sample

624

Patients

Duration

3 mo

Median

Setting

Multicenter, US

Population Patients with acute ischemic stroke presenting within 3 hours of symptom onset with a measurable deficit on the NIH Stroke Scale and no evidence of hemorrhage on head CT.

Intervention Intravenous recombinant tissue plasminogen activator (rt-PA) at 0.9 mg/kg (maximum 90 mg).

Comparator Placebo administered as an intravenous infusion.

Outcome Favorable functional outcome at 3 months, defined by scores on the Barthel Index, modified Rankin Scale, Glasgow Outcome Scale, and the National Institutes of Health Stroke Scale (NIHSS).

Study Limitations

• The study demonstrated an increased incidence of symptomatic intracranial hemorrhage, which poses a significant safety concern.

• The trial required 50% of participants to be enrolled and treated within 90 minutes of symptom onset, which may not be reflective of standard clinical practice or achievable in real-world settings.

• Baseline imbalances in stroke severity were noted in certain subgroups, specifically in the 91-180 minute enrollment cohort, sparking long-standing debate over the study's internal validity.

• The study was limited by the small sample size relative to the heterogeneity of stroke presentations, and it focused on a narrow 3-hour therapeutic window.

Clinical Significance

This trial serves as the foundational evidence for the use of intravenous alteplase in acute ischemic stroke, establishing the 3-hour therapeutic window that transformed stroke management from a largely supportive care model to an active reperfusion-focused intervention.

Historical Context

Prior to this landmark trial, there was no established effective pharmacological therapy for acute ischemic stroke, and clinicians were largely discouraged from using thrombolytics due to fears of fatal intracranial hemorrhage. The NINDS trial was the first to provide evidence of efficacy, leading to the FDA approval of rt-PA for acute ischemic stroke in 1996.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the biochemical mechanism of action for recombinant tissue plasminogen activator (rt-PA), and why does the NINDS trial emphasize a 3-hour window for its administration in acute ischemic stroke?

Key Response

rt-PA converts plasminogen to plasmin, which then degrades fibrin in thrombi to restore blood flow. The 3-hour window is critical because the 'penumbra' (salvageable brain tissue) diminishes over time, and the risk of reperfusion injury and hemorrhagic transformation increases as the blood-brain barrier degrades following prolonged ischemia.

Resident

The NINDS trial reported a 6.4% rate of symptomatic intracerebral hemorrhage (sICH) in the tPA group compared to 0.6% in the placebo group. How do you reconcile this increased risk with the finding that there was no significant difference in overall mortality between the two groups at three months?

Key Response

Despite the increase in early sICH, the functional benefits of successful recanalization in survivors outweighed the morbidity caused by the hemorrhages. The study showed that tPA patients were 30% more likely to have minimal or no disability at 3 months, indicating that the 'net' effect of the drug favors recovery even when accounting for bleeding risks.

Fellow

The NINDS trial used a two-part design. While Part 1 did not find a significant difference in the primary endpoint (4-point NIHSS improvement at 24 hours), Part 2 showed significant functional benefit at 3 months. What does this discrepancy suggest about early neurological assessment versus long-term functional recovery in stroke trials?

Key Response

Early neurological improvement (NIHSS) at 24 hours may not capture the full potential for brain plasticity and recovery. Functional scales like the modified Rankin Scale (mRS) or Barthel Index are more sensitive to the 'real-world' impact of thrombolysis. It suggests that immediate failure to 'improve' on a scale doesn't preclude a superior long-term outcome due to reduced infarct volume or improved collateralization.

Attending

Given the 'time is brain' paradigm established by NINDS, how should the trial's findings influence modern systems of care, such as the implementation of Mobile Stroke Units or 'drip-and-ship' protocols, especially in the era of mechanical thrombectomy?

Key Response

NINDS established that every minute counts; current guidelines emphasize 'door-to-needle' times under 60 (or even 45) minutes. Even though mechanical thrombectomy (MT) is now standard for large vessel occlusions (LVO), the NINDS trial remains the foundation for bridging therapy, as IV tPA can be initiated immediately while MT is being arranged, potentially recanalizing the vessel or softening the clot before intervention.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of the 'Global Statistic' (Wald test) employed in Part 2 of the NINDS trial. Why might researchers choose a composite global endpoint over a single primary outcome measure like the mRS?

Key Response

The global statistic combines multiple outcome measures (mRS, NIHSS, Barthel, Glasgow Outcome Scale) to increase statistical power and reduce the risk of Type I errors from multiple comparisons. In stroke research, where disability is multidimensional, a global test captures a broader spectrum of recovery than a single scale might, though it can complicate the interpretation of which specific functional domain was most affected.

Journal Editor

A common post-publication critique of the NINDS trial involves a baseline imbalance in stroke severity (NIHSS) between the treatment and placebo groups. As an editor, how would you evaluate the validity of the results if the treatment group had a higher proportion of 'mild' strokes at baseline?

Key Response

A baseline imbalance favoring the treatment group could lead to an overestimation of efficacy. However, a journal editor would look for sensitivity analyses or adjusted models. In the case of NINDS, subsequent independent re-analyses (e.g., by the FDA and the Ingall re-evaluation) confirmed that even after adjusting for baseline NIHSS, the benefit of tPA remained statistically significant, maintaining the study's integrity.

Guideline Committee

The NINDS trial excluded patients over age 80 and those with prior stroke plus diabetes. How have current AHA/ASA guidelines evolved regarding these specific subgroups based on post-NINDS evidence like ECASS III or IST-3?

Key Response

While the original NINDS criteria were strict, current AHA/ASA guidelines (Class I, Level of Evidence A) have expanded the use of IV alteplase to include patients >80 within the 0-3 hour window. Although the risk of sICH is higher in the elderly, the absolute benefit remains significant. The 3-4.5 hour window remains more restrictive for patients >80 and those with a history of both stroke and diabetes, though recent data continue to challenge these exclusions.

Clinical Landscape

Noteworthy Related Trials

1997

IST Trial

n = 19,435 · Lancet

Tested

Aspirin 300mg daily

Population

Patients with acute ischemic stroke

Comparator

Placebo

Endpoint

Death or dependency at 6 months

Key result: Aspirin initiated within 48 hours of ischemic stroke reduced the risk of death and recurrence without significantly increasing hemorrhagic complications.

2008

ECASS III Trial

n = 821 · NEJM

Tested

Intravenous alteplase

Population

Patients with acute ischemic stroke

Comparator

Placebo

Endpoint

Disability at 90 days (mRS 0-1)

Key result: Intravenous alteplase administered between 3 and 4.5 hours after the onset of symptoms significantly improved clinical outcomes.

2015

MR CLEAN Trial

n = 500 · NEJM

Tested

Endovascular mechanical thrombectomy

Population

Patients with acute ischemic stroke due to large-vessel occlusion

Comparator

Usual care (including IV tPA)

Endpoint

Functional status at 90 days (mRS)

Key result: Endovascular treatment plus usual care was more effective than usual care alone in patients with proximal arterial occlusions.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis